OBJECTIVE: To evaluate the prevalence of atypical antipsychotic use in privately insured children and the diagnoses associated with treatment. STUDY DESIGN: Claims were used to conduct a retrospective cohort study of children aged 2 through 18 years in the Midwest, covered by private insurance between 2002 and 2005 (n = 172,766). The 1-year prevalence of children receiving atypical antipsychotics was determined along with associated diagnoses. RESULTS: The 1-year prevalence of atypical antipsychotics ranged from 7.9 per 1000 in 2002 to 9.0 in 2005. The leading diagnoses were disruptive behavior disorders (67%), mood disorders (65%), and anxiety disorders (43%).The authors found that 75% of children on atypical antipsychotics had more than one psychiatric diagnosis. CONCLUSIONS: Atypical antipsychotic use is primarily seen in children who have multiple psychiatric diagnoses. Studies are needed to assess the long-term safety and effectiveness in such patients with multiple diagnoses.
OBJECTIVE: To evaluate the prevalence of atypical antipsychotic use in privately insured children and the diagnoses associated with treatment. STUDY DESIGN: Claims were used to conduct a retrospective cohort study of children aged 2 through 18 years in the Midwest, covered by private insurance between 2002 and 2005 (n = 172,766). The 1-year prevalence of children receiving atypical antipsychotics was determined along with associated diagnoses. RESULTS: The 1-year prevalence of atypical antipsychotics ranged from 7.9 per 1000 in 2002 to 9.0 in 2005. The leading diagnoses were disruptive behavior disorders (67%), mood disorders (65%), and anxiety disorders (43%).The authors found that 75% of children on atypical antipsychotics had more than one psychiatric diagnosis. CONCLUSIONS: Atypical antipsychotic use is primarily seen in children who have multiple psychiatric diagnoses. Studies are needed to assess the long-term safety and effectiveness in such patients with multiple diagnoses.
Authors: Jan Croonenberghs; Joerg M Fegert; Robert L Findling; Goedele De Smedt; Stefan Van Dongen Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-01 Impact factor: 8.829
Authors: William G Kronenberger; Ann L Giauque; Deborah E Lafata; Bradley N Bohnstedt; Laura E Maxey; David W Dunn Journal: J Child Adolesc Psychopharmacol Date: 2007-06 Impact factor: 2.576
Authors: Nick C Patel; Monica Hariparsad; Mary Matias-Akthar; Michael T Sorter; Drew H Barzman; John A Morrison; Kevin E Stanford; Stephen M Strakowski; Melissa P DelBello Journal: J Child Adolesc Psychopharmacol Date: 2007-06 Impact factor: 2.576
Authors: Michael L Birnbaum; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; John M Kane; Christoph U Correll Journal: Curr Psychiatry Rep Date: 2013-08 Impact factor: 5.285
Authors: Robert L Findling; Sarah McCue Horwitz; Boris Birmaher; Robert A Kowatch; Mary A Fristad; Eric A Youngstrom; Thomas W Frazier; David Axelson; Neal Ryan; Christine A Demeter; Judith Depew; Benjamin Fields; Mary Kay Gill; Elizabeth A Deyling; Brieana M Rowles; L Eugene Arnold Journal: J Child Adolesc Psychopharmacol Date: 2011-08 Impact factor: 2.576
Authors: Xuerong Wen; Oluwadolapo D Lawal; Nicholas Belviso; Kelly L Matson; Shuang Wang; Brian J Quilliam; Kimford J Meador Journal: Drug Saf Date: 2021-06-07 Impact factor: 5.606